These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8027950)

  • 1. An efficient control strategy for dosage regimens.
    Hu C; Lovejoy WS; Shafer SL
    J Pharmacokinet Biopharm; 1994 Feb; 22(1):73-94. PubMed ID: 8027950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of some control strategies for three-compartment PK/PD models.
    Hu C; Lovejoy WS; Shafer SL
    J Pharmacokinet Biopharm; 1994 Dec; 22(6):525-50. PubMed ID: 7473080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?
    Tod MM; Padoin C; Petitjean O
    Clin Pharmacokinet; 2001; 40(11):803-14. PubMed ID: 11735603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Bayesian estimation of pharmacokinetic parameters.
    Tsuchiwata S; Mihara K; Yafune A; Ogata H
    Ther Drug Monit; 2005 Feb; 27(1):18-24. PubMed ID: 15665741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control.
    Jelliffe RW; Schumitzky A; Van Guilder M; Liu M; Hu L; Maire P; Gomis P; Barbaut X; Tahani B
    Ther Drug Monit; 1993 Oct; 15(5):380-93. PubMed ID: 8249044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting.
    Proost JH
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):531-6. PubMed ID: 8574501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hierarchical Bayesian approach to population pharmacokinetic modelling.
    Smith A; Wakefield J
    Int J Biomed Comput; 1994 Jun; 36(1-2):35-42. PubMed ID: 7927858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian hierarchical modeling of receptor occupancy in PET trials.
    Vandenhende F; Renard D; Nie Y; Kumar A; Miller J; Tauscher J; Witcher J; Zhou Y; Wong DF
    J Biopharm Stat; 2008; 18(2):256-72. PubMed ID: 18327720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: a sensitivity analysis.
    Vozeh S; Steiner C
    J Pharmacokinet Biopharm; 1987 Oct; 15(5):511-28. PubMed ID: 3694495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian forecasting in paediatric populations.
    Fernández de Gatta MM; García MJ; Lanao JM; Domínguez-Gil A
    Clin Pharmacokinet; 1996 Nov; 31(5):325-30. PubMed ID: 9118582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of dosage regimens: a multiple model stochastic control approach.
    Bayard DS; Milman MH; Schumitzky A
    Int J Biomed Comput; 1994 Jun; 36(1-2):103-15. PubMed ID: 7927848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.
    Sheiner LB; Beal SL
    J Pharm Sci; 1982 Dec; 71(12):1344-8. PubMed ID: 7153881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamical dosage regimen calculations in linear pharmacokinetics.
    Iliadis A; Bruno R; Cano JP
    Comput Biomed Res; 1988 Jun; 21(3):203-20. PubMed ID: 3383552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust Bayesian decision theory applied to optimal dosage.
    Abraham C; Daurès JP
    Stat Med; 2004 Apr; 23(7):1055-73. PubMed ID: 15057878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive control of drug dosage regimens: basic foundations, relevant issues, and clinical examples.
    Jelliffe RW; Maire P; Sattler F; Gomis P; Tahani B
    Int J Biomed Comput; 1994 Jun; 36(1-2):1-23. PubMed ID: 7927847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients.
    Saint-Marcoux F; Marquet P; Jacqz-Aigrain E; Bernard N; Thiry P; Le Meur Y; Rousseau A
    Clin Pharmacokinet; 2006; 45(9):905-22. PubMed ID: 16928152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual dose optimization: why and how.
    Jelliffe R
    Int J Clin Pharmacol Ther; 2004 Mar; 42(3):183-4. PubMed ID: 15049439
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
    Peng B; Boddy AV; Cole M; Pearson AD; Chatelut E; Rubie H; Newell DR
    Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.